Table 1 Demographics
Unvaccinated sJIA (n = 50) | Vaccinated sJIA (n = 81) | Unvaccinated sJIA + AOSD (n = 51) | Vaccinated sJIA + AOSD (n = 99) | |||
|---|---|---|---|---|---|---|
Age (years) | 7.5 (4, 9)*** | 11 (7, 14)*** | 8 (4, 9.5)*** | 12 (8,18)*** | ||
Age of onset (years) | 2 (1, 4)*** | 5 (1, 9)*** | 2 (1, 4.5)*** | 7 (2, 12.5)*** | ||
Female Sex | 28 (56%)* | 63 (78%)* | 29 (57%)* | 79 (80%)* | ||
Country | ||||||
USA | 38 (76%) | 65 (80%) | 39 (76%) | 73 (73%) | ||
United Kingdom | 1 (2%) | 4 (5%) | 1 (2%) | 8 (8%) | ||
Canada | 1 (2%) | 3 (4%) | 1 (2%) | 7 (7%) | ||
Australia | 3 (6%) | 5 (6%) | 3 (6%) | 6 (6%) | ||
Other | 7 (14%) | 4 (5%) | 7 (14%) | 5 (5%) | ||
History of complications | ||||||
MAS | 25 (50%) | 45 (56%) | 25 (49%) | 49 (50%) | ||
Lung Disease | 15 (30%) | 16 (20%) | 15 (29%) | 17 (17%) | ||
Arthritis | 26 (52%) | 43 (53%) | 26 (51%) | 50 (50%) | ||
Pericarditis/myocarditis | 4 (8%) | 8 (10%) | 4 (8%) | 10 (10%) | ||
History of Disease flare or severe side effects with other immunizations | 12 (24%)*** | 1 (1%)*** | 12 (24%)*** | 4 (4%)*** | ||
Total number of medications ever used beyond NSAIDs | 7 (3, 8)* | 5 (3, 7)* | 7 (2.5, 8)* | 4 (3, 6)* |